<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="section" /><meta name="keywords" content="Beta-adrenoceptor blocking drugs; Beta-blockers see Beta-adrenoceptor blocking drugs; Labetalol; Celiprolol; Carvedilol; Nebivolol; Antihypertensives: beta-blockers; Hypertension: beta-blockers; Beta-adrenoceptor blocking drugs: hypertension; Phaeochromocytoma; Beta-adrenoceptor blocking drugs: angina; Angina: management: beta-blockers; Beta-adrenoceptor blocking drugs: myocardial infarction; Myocardial infarction: management: beta-blockers; Beta-adrenoceptor blocking drugs: arrhythmias; Arrhythmias: beta-blockers; Esmolol; Sotalol: cardiovascular; Beta-adrenoceptor blocking drugs: heart failure; Heart failure: beta-blockers; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers" /><meta name="IX" content="Beta-adrenoceptor blocking drugs; Labetalol; Celiprolol; Carvedilol; Nebivolol; Antihypertensives: beta-blockers; Hypertension: beta-blockers; Beta-adrenoceptor blocking drugs: hypertension; Phaeochromocytoma; Beta-adrenoceptor blocking drugs: angina; Angina: management: beta-blockers; Beta-adrenoceptor blocking drugs: myocardial infarction; Myocardial infarction: management: beta-blockers; Beta-adrenoceptor blocking drugs: arrhythmias; Arrhythmias: beta-blockers; Esmolol; Sotalol: cardiovascular; Beta-adrenoceptor blocking drugs: heart failure; Heart failure: beta-blockers; Beta-adrenoceptor blocking drugs: thyrotoxicosis; Thyrotoxicosis: beta-blockers" /><meta name="IXN" content="Beta-blockers see Beta-adrenoceptor blocking drugs" /><title>2.4 Beta-adrenoceptor blocking drugs: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../theme/theme.css" /><link type="text/css" rel="stylesheet" href="../../theme/print.css" media="print" /><link type="text/css" rel="stylesheet" href="265/style.css" /><link type="image/x-icon" rel="shortcut icon" href="favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="35091.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="2455.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.7.0/jquery.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.tooltip.min.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.cookie.js"></script><script type="text/javascript" src="../../scripts/jquery/jquery.autosuggest.js"></script><script type="text/javascript" src="../../scripts/scripts.js"></script><style type="text/css">
  .contentsbox { position: fixed; z-index:1001;}
  .contentsbox_wrap {overflow:hidden;width:20px;height:130px; position:absolute;left:0;top:0;}
</style><!--[if lte IE 7]>
          <style type="text/css">
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }
          </style>
          <![endif]--></head><body><?highlighter off?><div id="pU"><a id="pD" accesskey="s" rel="bookmark" href="2455.htm#pB" title="Skip Navigation">Skip Navigation</a><ul id="pZ"><li><a href="http://www.medicinescomplete.com/mc/account.htm">You are signed in as a member of <b>BNF.org Free Access</b></a></li><li> | <a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li> | <a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul><a href="http://www.medicinescomplete.com/mc/" title="Go to the MedicinesComplete home page"><img src="../../images/mc.png" alt="MedicinesComplete" /></a><ul id="pM"><li><a href="http://www.medicinescomplete.com/mc/" class="selected" accesskey="1" title="Home: access key 1"><strong><span>Home</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/"><strong><span>Welcome</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=2455.htm" accesskey="9" title="Feedback: access key 9"><strong><span>Feedback</span></strong></a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm" accesskey="6" title="Help button: access key 6"><strong><span>Help</span></strong></a></li></ul></div><div id="pA"><div id="pY">British National Formulary</div><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 26 May 2012 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="q">Search for</label><div id="qd"><div><input accesskey="4" type="text" id="q" name="q" /><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div><div id="pH"><div id="pN"><div id="pT"><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF No. 63 (March 2012)</a> &gt; <a href="1002.htm">2 Cardiovascular system</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="2441.htm" title="Previous: LIDOCAINE HYDROCHLORIDE">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="2456.htm" title="Next: PROPRANOLOL HYDROCHLORIDE">Next page</a> ►</div></div></div></div><div id="p1"><div id="pB"><h1 id="_2455">2.4 Beta-adrenoceptor blocking drugs</h1><?highlighter on?><div id="pC" class="jN"><div><p>Beta-adrenoceptor
blocking drugs (beta-blockers) block the beta-adrenoceptors in the
heart, peripheral vasculature, bronchi, pancreas, and liver.</p><p>Many beta-blockers are now available and in general they are
all equally effective. There are, however, differences between them,
which may affect choice in treating particular diseases or individual
patients.</p><p>Intrinsic sympathomimetic activity (ISA, partial agonist activity)
represents the capacity of beta-blockers to stimulate as well as to
block adrenergic receptors. <b>Oxprenolol</b>, <b>pindolol</b>, <b>acebutolol</b>, and <b>celiprolol</b> have
intrinsic sympathomimetic activity; they tend to cause less bradycardia
than the other beta-blockers and may also cause less coldness of the
extremities. </p><p>Some beta-blockers are lipid soluble and some are water soluble. <b>Atenolol</b>, <b>celiprolol</b>, <b>nadolol</b>, and <b>sotalol</b> are the most water-soluble; they are
less likely to enter the brain, and may therefore cause less sleep
disturbance and nightmares. Water-soluble beta-blockers are excreted
by the kidneys and dosage reduction is often necessary in renal impairment. </p><p>Beta-blockers with a relatively short duration of action have
to be given two or three times daily. Many of these are, however,
available in modified-release formulations so that administration
once daily is adequate for hypertension. For angina twice-daily treatment
may sometimes be needed even with a modified-release formulation.
Some beta-blockers, such as <span>atenolol</span>, <span>bisoprolol</span>, <span>carvedilol</span>, <span>celiprolol</span>, and <span>nadolol</span>, have an intrinsically longer duration
of action and need to be given only once daily.</p><p><span id="_2455.6">Beta-blockers
slow the heart and can depress the myocardium; they are contra-indicated
in patients with second- or third-degree
heart block. Beta-blockers should also be avoided in patients
with worsening unstable heart failure; care
is required when initiating a beta-blocker in those with stable heart failure (see also <a title="topic: Heart failure" href="119651.htm#_119651">section 2.5.5</a>). </span><span id="_2455.7"><b>Sotalol</b> may
prolong the QT interval, and it occasionally
causes life-threatening ventricular arrhythmias (<b>important:</b> particular care is required to avoid
hypokalaemia in patients taking sotalol).</span></p><p><b>Labetalol</b>, <b>celiprolol</b>, <b>carvedilol</b>, and <b>nebivolol</b> are beta-blockers
that have, in addition, an arteriolar vasodilating action, by diverse
mechanisms, and thus lower peripheral resistance. There is no evidence
that these drugs have important advantages over other beta-blockers
in the treatment of hypertension.</p><div id="_2455.1"><p>Beta-blockers can precipitate bronchospasm and should therefore usually be avoided
in patients with a history of asthma. When there is no
suitable alternative, it may be necessary for a patient with well-controlled
asthma, or chronic obstructive pulmonary disease (without significant
reversible airways obstruction), to receive treatment with a beta-blocker
for a co-existing condition (e.g. heart failure or following myocardial
infarction). In this situation, a cardioselective beta-blocker should
be selected and initiated at a low dose by a specialist; the patient
should be closely monitored for adverse effects. <b><span>Atenolol</span></b>, <b><span>bisoprolol</span></b>, <b><span>metoprolol</span></b>, <b><span>nebivolol</span></b>, and (to a lesser extent) <b><span>acebutolol</span></b>, have less effect on the beta<sub>2</sub> (bronchial) receptors and are, therefore, relatively <i>cardioselective</i>, but they are not <i>cardiospecific</i>. They have a lesser effect on airways resistance but are not free
of this side-effect.</p><p>Beta-blockers are also associated with fatigue, coldness of
the extremities (may be less common with those with ISA, see above),
and sleep disturbances with nightmares (may be less common with the
water-soluble beta-blockers, see above). </p><p>Beta-blockers can affect carbohydrate metabolism, causing hypoglycaemia
or hyperglycaemia in patients with or without diabetes; they can also
interfere with metabolic and autonomic responses to hypoglycaemia, thereby
masking symptoms such as tachycardia. However, beta-blockers are not
contra-indicated in diabetes, although the cardioselective beta-blockers
(see above) may be preferred. Beta-blockers should be avoided altogether
in those with frequent episodes of hypoglycaemia. Beta-blockers, especially when combined with a thiazide diuretic,
should be avoided for the routine treatment of uncomplicated hypertension
in patients with diabetes or in those at high risk of developing diabetes.</p></div><div id="_203966"><div class="cAZ"><h2>Pregnancy</h2> <p class="cAX">Beta-blockers may cause intra-uterine
growth restriction, neonatal hypoglycaemia, and bradycardia; the risk
is greater in severe hypertension. The use of labetalol in maternal
hypertension is not known to be harmful, except possibly in the first
trimester. Information on the safety of carvedilol during pregnancy
is lacking. If beta-blockers are used close to delivery, infants should
be monitored for signs of beta-blockade (and alpha-blockade with labetalol
or carvedilol). For the treatment of hypertension in pregnancy, see <a title="BNF:target-block: Hypertension in pregnancy" href="2534.htm#_200338">section 2.5</a>.</p></div></div><div id="_203967"><div class="cAZ"><h2>Breast-feeding</h2> <p class="cAX">Infants should be monitored as
there is a risk of possible toxicity due to beta-blockade (and alpha-blockade
with labetalol or carvedilol), but the amount of most beta-blockers
present in milk is too small to affect infants. Acebutolol, atenolol,
nadolol, and sotalol are present in milk in greater amounts than other
beta-blockers. The manufacturers of celiprolol, esmolol, and nebivolol
advise avoidance if breast-feeding.</p></div><div class="cAZ" id="_2455.2"><h2>Hypertension</h2> <p class="cAX">The mode of action of beta-blockers in hypertension is not understood,
but they reduce cardiac output, alter baroceptor reflex sensitivity,
and block peripheral adrenoceptors. Some beta-blockers depress plasma
renin secretion. It is possible that a central effect may also partly
explain their mode of action.</p><p>Beta-blockers are effective for reducing blood pressure but
other antihypertensives (<a title="section: Drugs affecting the renin-angiotensin system and some other antihypertensive drugs" href="2534.htm#_2534">section 2.5</a>) are usually
more effective for reducing the incidence of stroke, myocardial infarction,
and cardiovascular mortality, especially in the elderly. Other antihypertensives
are therefore preferred for routine initial treatment of uncomplicated
hypertension.</p><p>In general, the dose of a beta-blocker does not have to be high;
for example, atenolol is given in a dose of 25–50 mg daily and it
is rarely necessary to increase the dose to 100 mg.</p> <p class="cAX">Beta-blockers can be used to control the pulse rate in patients
with <i>phaeochromocytoma</i> (<a title="monograph-family: Phaeochromocytoma" href="19158.htm#_19158">section 2.5.4</a>). However, they should never
be used alone as
beta-blockade without concurrent alpha-blockade may lead to a hypertensive
crisis. For this reason phenoxybenzamine should always be used together
with the beta-blocker.</p></div></div><div class="cAZ"><h2>Angina</h2> <p class="cAX">By reducing cardiac work beta-blockers
improve exercise tolerance and relieve symptoms in patients with <i>angina</i> (for further details on the management of stable
angina and acute coronary syndromes, see <a title="BNF:sub-section: Management of myocardial infarction" href="60552.htm#_60552">section 2.10.1</a>). As
with hypertension there is no good evidence of the superiority of
any one drug, although occasionally a patient will respond better
to one beta-blocker than to another. There is some evidence that sudden withdrawal may cause an exacerbation of angina and therefore gradual reduction of dose is preferable when beta-blockers
are to be stopped. There is a risk of precipitating heart failure
when beta-blockers and verapamil are used together in established
ischaemic heart disease (<b>important</b>: see VERAPAMIL <a title=" Calcium-channel blockers" href="2616.htm#_2616">section 2.6.2</a>).</p></div><div class="cAZ"><h2>Myocardial infarction</h2> <p class="cAX">For
advice on the management of ST-segment elevation myocardial infarction
and non-ST-segment elevation myocardial infarction, see <a title=" Management of myocardial infarction" href="60552.htm#_60552">section 2.10.1</a>. Several studies have shown
that some beta-blockers can reduce the recurrence rate of <i>myocardial infarction</i>. However, uncontrolled heart failure,
hypotension, bradyarrhythmias, and obstructive airways disease render
beta-blockers unsuitable in some patients following a myocardial infarction. <b>Atenolol</b> and <b>metoprolol</b> may reduce early
mortality after intravenous and subsequent oral administration in
the acute phase, while <b>acebutolol</b>, <b>metoprolol</b>, <b>propranolol</b>, and <b>timolol</b> have
protective value when started in the early convalescent phase. The
evidence relating to other beta-blockers is less convincing; some
have not been tested in trials of secondary prevention. Sudden cessation of a beta-blocker can cause a rebound worsening
of myocardial ischaemia.</p></div><div id="_2455.5"><div class="cAZ" id="_120503"><h2>Arrhythmias</h2> <p class="cAX">Beta-blockers act as <i>anti-arrhythmic
drugs </i>principally by attenuating the effects of the sympathetic
system on automaticity and conductivity within the heart. They can
be used in conjunction with <span>digoxin</span> to control
the ventricular response in atrial fibrillation, especially in patients
with thyrotoxicosis. Beta-blockers are also useful in the management
of supraventricular tachycardias, and are used to control those following
myocardial infarction (see above). </p><p><b>Esmolol</b> is a relatively cardioselective beta-blocker with a very short duration
of action, used intravenously for the short-term treatment of supraventricular
arrhythmias, sinus tachycardia, or hypertension, particularly in the
peri-operative period. It may also be used in other situations, such
as acute myocardial infarction, when sustained beta-blockade might
be hazardous.</p> <p class="cAX"><b>Sotalol</b>, a non-cardioselective beta-blocker with additional
class III anti-arrhythmic activity, is used for prophylaxis in paroxysmal
supraventricular arrhythmias. It also suppresses ventricular ectopic
beats and non-sustained ventricular tachycardia. It has been shown
to be more effective than lidocaine in the termination of spontaneous
sustained ventricular tachycardia due to coronary disease or cardiomyopathy.
However, it may induce torsade de pointes in susceptible
patients.</p></div></div><div class="cAZ"><h2>Heart failure</h2> <p class="cAX">Beta-blockers may produce benefit
in heart failure by blocking sympathetic activity. <b><span>Bisoprolol</span></b> and <b><span><span>carvedilol</span></span></b> reduce mortality in any grade of stable heart
failure; <b>nebivolol</b> is licensed for stable mild to
moderate heart failure in patients over 70 years. Treatment should
be initiated by those experienced in the management of heart failure
(<a title=" Drugs affecting the renin-angiotensin system" href="27510.htm#_27510">section 2.5.5</a>).</p></div><div id="_200409"><div class="cAZ"><h2>Thyrotoxicosis</h2> <p class="cAX">Beta-blockers are used
in pre-operative preparation for thyroidectomy. Administration of
propranolol can reverse clinical symptoms of <i>thyrotoxicosis</i> within 4 days. Routine tests of increased thyroid function remain
unaltered. The thyroid gland is rendered less vascular thus making
surgery easier (<a title=" Antithyroid drugs" href="4242.htm#_4242">section 6.2.2</a>).</p></div></div><div class="cAZ"><h2>Other uses</h2> <p class="cAX">Beta-blockers have been used to alleviate
some symptoms of <i>anxiety</i>; probably patients with
palpitation, tremor, and tachycardia respond best (see also <a title=" Anxiolytics" href="3169.htm#_3169">section
4.1.2</a> and <a title=" Drugs used in essential tremor, chorea, tics, and related disorders" href="3671.htm#_3671">section 4.9.3</a>). Beta-blockers
are also used in the <i>prophylaxis of migraine</i> (<a title=" Prophylaxis of migraine" href="3566.htm#_3566">section 4.7.4.2</a>). Betaxolol, carteolol, levobunolol,
and timolol are used topically in <i>glaucoma</i> (<a title=" Treatment of glaucoma" href="5483.htm#_5483">section 11.6</a>).</p></div></div></div><?highlighter on?><div id="pS"><p>Sub-sections</p><ul class="jT"><li id="_2456"><a href="2456.htm" title="PROPRANOLOL HYDROCHLORIDE">PROPRANOLOL HYDROCHLORIDE</a></li><li id="_2464"><a href="2464.htm" title="ACEBUTOLOL">ACEBUTOLOL</a></li><li id="_2468"><a href="2468.htm" title="ATENOLOL">ATENOLOL</a></li><li id="_2481"><a href="2481.htm" title="BISOPROLOL FUMARATE">BISOPROLOL FUMARATE</a></li><li id="_27351"><a href="27351.htm" title="CARVEDILOL">CARVEDILOL</a></li><li id="_2484"><a href="2484.htm" title="CELIPROLOL HYDROCHLORIDE">CELIPROLOL HYDROCHLORIDE</a></li><li id="_200405"><a href="200405.htm" title="CO-TENIDONE">CO-TENIDONE</a></li><li id="_2486"><a href="2486.htm" title="ESMOLOL HYDROCHLORIDE">ESMOLOL HYDROCHLORIDE</a></li><li id="_2488"><a href="2488.htm" title="LABETALOL HYDROCHLORIDE">LABETALOL HYDROCHLORIDE</a></li><li id="_2491"><a href="2491.htm" title="METOPROLOL TARTRATE">METOPROLOL TARTRATE</a></li><li id="_2502"><a href="2502.htm" title="NADOLOL">NADOLOL</a></li><li id="_77278"><a href="77278.htm" title="NEBIVOLOL">NEBIVOLOL</a></li><li id="_2507"><a href="2507.htm" title="OXPRENOLOL HYDROCHLORIDE">OXPRENOLOL HYDROCHLORIDE</a></li><li id="_2517"><a href="2517.htm" title="PINDOLOL">PINDOLOL</a></li><li id="_2521"><a href="2521.htm" title="SOTALOL HYDROCHLORIDE">SOTALOL HYDROCHLORIDE</a></li><li id="_2527"><a href="2527.htm" title="TIMOLOL MALEATE">TIMOLOL MALEATE</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="2441.htm">Previous: LIDOCAINE HYDROCHLORIDE</a> | <a class="top" href="2455.htm#">Top</a> | <a accesskey="]" href="2456.htm">Next: PROPRANOLOL HYDROCHLORIDE</a> ►</div></div></div><div id="pF"><div id="pL"><div id="footer"><div id="footerinner"><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a> | </li><li><a href="http://www.medicinescomplete.com/mc/marketing/current/contact.htm">Contact Us</a> | </li><li><a href="privacy.htm" title="Privacy Policy">Privacy Policy</a> | </li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a> | </li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div></div></div><div id="pX"><p><a href="35091.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2012. All rights reserved.</a></p></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>